To further evaluate the immunomodulatory role of APOBEC3A in restriction of HIV-1 infection, MDM were untreated or treated with control siRNA or APOBEC3A siRNA (A3A siRNA) 24 h prior to ALFQ treatment (Fig. 10 and S6). This evidence concerns the gene APOBEC3A and HIV-1 infection.